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ZebraﬁshCerebral cavernous malformations (CCMs) are vascular anomalies of the central nervous system that arise
due to mutations in genes encoding three unrelated proteins: CCM1 (KRIT1); CCM2 (Malcavernin/OSM)
and CCM3 (PDCD10). Both biochemical and mutant studies suggest that CCM1 and CCM2 act as part of a
physical complex to regulate vascular morphogenesis and integrity. In contrast, mouse Ccm3 mutant and in
vitro cell culture data suggests an independent role for Ccm3. In this study, we sought to use the zebraﬁsh
model system to examine for the ﬁrst time the role of ccm3 in cranial vessel development. We report that in-
hibition of zebraﬁsh ccm3a/b causes heart and circulation defects distinct from those seen in ccm1 (santa) and
ccm2 (valentine) mutants, and leads to a striking dilation and mispatterning of cranial vessels reminiscent of
the human disease pathology. ccm3, but not ccm2, defects can be rescued upon overexpression of stk25b, a
GCKIII kinase previously shown to interact with CCM3. Morpholino knockdown of the GCKIII gene stk25b re-
sults in heart and vasculature defects similar to those seen in ccm3morphants. Finally, additional loss of ccm3
in ccm2 mutants leads to a synergistic increase in cranial vessel dilation. These results support a model in
which CCM3 plays a role distinct from CCM1/2 in CCM pathogenesis, and acts via GCKIII activity to regulate
cranial vasculature integrity and development. CCM3/GCKIII activity provides a novel therapeutic target for
CCMs, as well as for the modulation of vascular permeability.
© 2011 Elsevier Inc. All rights reserved.Introduction
Cerebral Cavernous Malformations (CCMs) are prevalent vascular
abnormalities, affecting the blood vessels of the central nervous sys-
tem in up to 0.5% of the population (Labauge et al., 2007; Revencu
and Vikkula, 2006). They are characterized by dilated, thin-walled
vascular channels and can lead to strokes, seizures and death due to
recurrent brain hemorrhages. Familial cases of CCMs, which account
for up to 40% of clinical presentation, are mainly due to mutations
in one of three genes: CCM1 (KRIT1), CCM2 (Malcavernin/OSM), and
CCM3 (PDCD10) (Bergametti et al., 2005; Denier et al., 2004; Eerola
et al., 2000; Guclu et al., 2005; Gunel et al., 1995; Liquori et al.,
2003; Sahoo et al., 1999). In familial cases, an autosomal dominanterebral cavernous malforma-
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rights reserved.form of inheritance is evident (Stahl et al., 2008). However, recent
use of Ccm1 and Ccm2 mutant mouse models, as well as analysis of
CCM patient lesion endothelial cells, has strongly suggested a two-
hit mechanism for this disease, where malformations arise from a so-
matic loss of the second wildtype allele (Akers et al., 2009; Chan et al.,
2011; Gault et al., 2005, 2009; McDonald et al., 2011; Pagenstecher
et al., 2009; Plummer et al., 2004).
Identiﬁcation of the three CCM disease genes has directed research
into the mechanism of CCM pathology. CCM1-3 encode for distinct
and unrelated scaffold proteins that lack obvious enzymatic function.
The characterization of CCM1 and CCM2 biochemical activities has
been the subject of great scrutiny. CCM1, which contains two NPxYmo-
tifs, three ankyrin repeats, and a C-terminal FERMdomain, binds the en-
dothelial cell-cell junction stabilizer Rap1, and associates with other
junctional proteins such as β-catenin, ICAP-1, and Vascular-
Endothelial (VE)-Cadherin (Glading et al., 2007; Lampugnani et al.,
2010; Zawistowski et al., 2002; Zhang et al., 2001). CCM2, which con-
tains a phosphotyrosine binding (PTB) domain, directly interacts with
MEKK3, and the GTPases Rac and RhoA, and is thought to balance the
activities of RhoA and Cdc42 in endothelial cells (Borikova et al., 2010;
Crose et al., 2009; Glading et al., 2007; Hilder et al., 2007; Liquori
et al., 2003; Stockton et al., 2010; Uhlik et al., 2003; Whitehead et al.,
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overexpressed CCM1 and CCM2 proteins demonstrate that they physi-
cally interact and exist as part of a complex (Zawistowski et al., 2005;
Zhang et al., 2007). In cultured endothelial cells, reduction of CCM1 or
CCM2 levels leads to a decrease in vessel-like tube formation, increase
in formation of actin stress ﬁbers, and increased permeability of the en-
dothelial layer, which is mediated at least in part by elevated RhoA ac-
tivity (Glading et al., 2007; Whitehead et al., 2009). In mice,
endothelial-speciﬁc deletion of Ccm1 or Ccm2 leads to identical angio-
genesis defects that result in mid-gestation lethality, suggesting that
CCM1/2 complex activity is required primarily in endothelial cells
(Boulday et al., 2009;Whitehead et al., 2004, 2009). Ccm2 heterozygous
mutant mice do display increased leakiness in adult subcutaneous ves-
sels, which can be alleviated by pharmacological inhibition of RhoA
(Whitehead et al., 2009). Zebraﬁsh with null mutations in the ccm1
(santa, san) or ccm2 (valentine, vtn) genes display an identical dilated
heart phenotype accompanied with vascular defects, including dilation
of the sub-intestinal vessels and posterior cardinal vein (Hogan et al.,
2008; Mably et al., 2006). Furthermore, gross dilation of the heart and
embryonic vessels in double san/vtn mutants are identical to those of
single mutants (Mably et al., 2006). This demonstrates non-redundant
and essential functions for ccm1 and ccm2 in zebraﬁsh cardiovascular
development, and correlates with biochemical analysis that shows the
two proteins are part of a physical complex.
Among the three CCM proteins, CCM3 is the most highly con-
served across vertebrate species (Chan et al., 2010). However, due
to its later discovery and until recently lack of identiﬁable domains,
CCM3's function remains poorly understood. Clinically, a signiﬁcantly
larger proportion of patients with mutations in CCM3 (as compared to
CCM1 or CCM2) exhibit an earlier age of disease onset, with a higher
occurrence of hemorrhage and more lesions evident by MRI (Denier
et al., 2006). Mice with either global or endothelial-restricted Ccm3
deletion die at an earlier stage than Ccm1 or Ccm2 null mice, and dis-
play severe defects in vasculogenesis as well as hematopoiesis (Chan
et al., 2011; He et al., 2010). Finally, gene knockdown in cultured en-
dothelial cells from sporadic CCM patients demonstrated distinct ac-
tivities for CCM3 and CCM1/2 (Chan et al., 2011; Zhu et al., 2010).
Taken together, these results suggest that CCM3 plays a role in endo-
thelial cells mechanistically separable from CCM1 and CCM2.
Recent studies have attributed a number of putative activities to
CCM3. CCM3 has been shown to interact with members of the
germinal-center kinase III (GCKIII) protein family; STK25 (YSK1/
SOK1), MST4 and STK24 (MST3) (Ceccarelli et al., 2011; Rual et al.,
2005; Voss et al., 2007). Activity of these kinases (and in some cases
CCM3) has been shown to regulate Golgi polarity, cell migration and
neurite outgrowth (Fidalgo et al., 2010; Matsuki et al., 2010). In the
mouse embryo, CCM3 has been shown to be essential for VEGFR2 sig-
naling (He et al., 2010). CCM3 has also been described as residing in
the STRiatin-Interacting Phosphatase And Kinase (STRIPAK) complex,
which contains STK25 and MST4, but not CCM1 or CCM2 (Goudreault
et al., 2009). In vitro, physical interaction of CCM3 with CCM1 and
CCM2 has been reported (Voss et al., 2007). Interactions of the CCM3
N-terminal domain with GCKII proteins, and the CCM3 C-terminal FAT
domain with the STRIPAK complex, CCM2 and Paxillin have been de-
scribed, suggesting that CCM3 acts to recruit GCKIIIs to protein com-
plexes (Kean et al., 2011; Li et al., 2010; Voss et al., 2009). Knockdown
of ccm3 function in zebraﬁsh by use of antisense morpholinos has
suggested that the ccm3 and ccm1/2 loss-of-function phenotypes are
identical, resulting in an enlarged heart, with Ccm3 potentially act-
ing (based on morpholino and tissue culture data) via Stk24 and 25
(Zheng et al., 2010).
The precise mechanism through which loss of CCM3 leads to CCM
disease therefore remains unknown. A critical need clearly exists to
study the function of CCM3 (and CCM1/2) in the proper context:
the cranial vasculature. Further, models are required to examine the
initial events and progression of CCMs, as at present only the diseaseend point is being examined. In this study, we employ detailed anal-
ysis of the cranial vasculature in ccm3 morpholino injected zebraﬁsh
embryos. Contrary to previous reports, we ﬁnd that inhibition of zeb-
raﬁsh ccm3a/b causes heart and circulation defects distinct from those
seen in san and vtnmutants. Strikingly, loss of ccm3a/b also leads to a
dilation and mispatterning of cranial vessels in the early zebraﬁsh
embryo, resembling the human disease pathology. Endothelial cells
are further found to have elevated protrusive activity, suggesting de-
fects in cell adhesion or junction stabilization. These phenotypes are
not observed in san or vtn mutants. We further ﬁnd that ccm3, but
not ccm1 or 2, heart and vasculature defects can be effectively rescued
upon overexpression of stk25b, placing GCKIII kinase activity down-
stream of CCM3 in a CCM disease-like condition. Morpholino knock-
down of the GCKIII gene stk25b results in cranial vasculature defects
similar to those seen in ccm3 morphants. Finally, we show that fur-
ther loss of ccm3 in ccm2 mutants leads to a synergistic increase in
cranial vessel dilations. Our results support a model in which CCM3
and CCM1/2 play distinct roles in CCM pathogenesis, and further
show that CCM3 acts via GCKIII activity to regulate proper cranial vas-
culature development. Given the optical clarity of the zebraﬁsh em-
bryo, ccm3 morphants provide an excellent model for live, real-time
analysis of the mechanisms, initiation and progression of CCM in vivo.
Materials and methods
Zebraﬁsh maintenance and imaging
Adult zebraﬁsh were maintained and embryos raised and staged
as previously described (Westerﬁeld, 1993). The san (ccm1s610), vtn
(ccm2s259) and sih (tnnt2ab109) mutants have been described previ-
ously (Mably et al., 2006; Sehnert et al., 2002). Tg(kdrl:EGFP)s843, Tg
(kdrl:HsHRAS-mCherry)s896, Tg(myl7:EGFP)twu34, Tg(gata1:dsRED)sd2,
Tg(myl7: HsHRAS-mCherry) and Tg(ﬂi1:nlsEGFP)y7 ﬁsh have been pre-
viously described (Beis et al., 2005; Chi et al., 2008; Huang et al.,
2003; Roman et al., 2002; Traver et al., 2003). For vasculature analy-
sis, adult zebraﬁsh carrying the kdrl:EGFP transgene and heterozygous
for mutation of san, vtn or sih were interbred, and mutants identiﬁed
by enlarged heart or the absence of cardiac contractions. For imaging,
transgenic embryos were raised at 28.5°C until appropriate stage at
which time they were mounted in 1% (w/v) low melting agarose
(Sigma) and imaged using a Zeiss LSM510 laser scanning confocal mi-
croscope outﬁtted with Plan-Neoﬂuar 10x (numerical aperture 0.3)
or Fluar 40x (numerical aperture 1.3) objective lenses. Close-up im-
ages of the endothelial cell protrusions on cranial vasculature were
imaged using a Zeiss Axiovert 200 equipped with a Hamamatsu Orca
AG CCD camera and spinning disk confocal scan head with a 40x ob-
jective lens (and 1.5x magniﬁcation, for 60x total). Z-stack projections
of confocal micrographs were assembled using Volocity software.
Microinjection of morpholino oligonucleotides and RNA overexpression
Standard techniques were used for microinjections (Westerﬁeld,
1993). Morpholino antisense oligonucleotides targeting ccm3a/b (5′-
CTTCATCTCTTCCATTGTCATCCTC-3′), ccm3a (5′-GATCGCTGAAAGGAA-
CACCAATGGG-3′), ccm3b (5′-ACATTATGTTCTCGCCTTACCCTCC-3′),
stk25a (5′-ATGTTCTGGAGGTGAGCCATATCCT-3′) and stk25b (5′-
TGCGCCATCTCAGTGGATGAGAGCA-3′) were purchased from Gene
Tools (Oregon, USA) andwere injected into one-cell stage zebraﬁsh em-
bryos at indicated doses and combinations. p53morpholino oligonucle-
otide (5′-GCGCCATTGCTTTGCAAGAATTG-3′) was co-injected with
ccm3a/b, stk25a and stk25bmorpholinos at 1.5 times the dose of the ex-
perimentalMO to reduce apoptotic cell death (Langheinrich et al., 2002;
Robu et al., 2007). Full-length zebraﬁsh ccm3b and stk25b coding se-
quences were ampliﬁed from 24 hpf zebraﬁsh cDNA. Coding sequences
were subcloned into pCS2+ and veriﬁed by sequencing for accuracy.
For mRNA production, vectors were linearized via NotI digestion and
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SP6 kit (Ambion).
Whole mount RNA in situ hybridization
Embryos were ﬁxed in 4% paraformaldehyde in phosphate-
buffered saline and stored in 100% methanol at −20°C. stk25b (NCBI
Gene ID: 406600) and ccm3a (NCBI Gene ID: 200555) riboprobes
were PCR ampliﬁed from cDNA and subcloned into pGEM-T Easy Vec-
tor (Promega). For riboprobe production, vectors were linearized, and
DIG-labeled probe synthesized in vitro using a DIG RNA Labeling Kit
(Roche). RNA in situ hybridization was performed as previously de-
scribed (Thisse and Thisse, 2008).
Antibody staining
54 hpf embryos were ﬁxed in 4% paraformaldehyde for 4 hours at
4°C. Embryos were then washed 3×5 min in PBS-Tx (PBS+0.1% Tri-
tonX100). PBS-Tx (PBS+0.5% TritonX-100) was used to permeabilize
the embryos for 4 h at room temperature (RT). Embryos were then
blocked in 2% normal goat serum (NGS) in 1 x PBS +1 x BSA +1%
DMSO+0.5% TritonX-100 (PBDT) for 30 min at RT. Embryoswere incu-
bated with primary antibodies in PBDT+2% NGS overnight at 4°C. Em-
bryos were then washed for 3 hours with several changes of PBS-Tx at
RT, and incubated in secondary antibodies diluted with PBDT+2%
NGS overnight at 4°C. Embryos were ﬁnally washed several times
with PBS-Tx at RT before imaging. The following antibodies were
used:mouse anti-ZO1 (1:200, Invitrogen), rabbit anti-GFP (1:1000, Tor-
rey Pines Biolabs), anti-mouse Alexa 568 (1:1000, Invitrogen) and anti-
rabbit Alexa 488 (1:200, Invitrogen).
Results
Simultaneous knockdown of ccm3a and ccm3b results in gross dilation
and mispatterning of cranial vessels
To address the in vivo function of ccm3 in zebraﬁsh development,
we inhibited function of the two zebraﬁsh ccm3 genes, ccm3a and
ccm3b, using a previously described morpholino (MO) that targets
their identical (by sequence) translation initiation sites (referred to
as ccm3a/b ATG MO) (Voss et al., 2009). Injection of 0.75 ng ccm3a/b
ATG MO into one-cell stage embryos resulted in cardiovascular de-
fects and a complete circulatory block. All morpholino injected (mor-
phant) embryos displayed a pronounced pericardial edema that also
extended to the ventral aspect of the yolk by 2 days post-
fertilization (dpf) (Fig. 1A). The lack of circulation in morphant em-
bryos could be clearly visualized using the double transgenic kdrl:
EGFP; gata1:dsRED line, which showed pooling of blood at the level
of the yolk (Fig. 1B). Most strikingly, inhibition of ccm3a/b led to a
gross dilation and mispatterning of cranial vessels, as imaged using
transgenic kdrl:EGFP embryos (where endothelial cells are marked
by EGFP expression). Confocal z-stack projections of dorsal head vas-
culature revealed abnormally thick prosencephalic artery (PrA), mes-
encephalic vein (MsV), and anterior cerebral vein (AceV) at 54 hours
post-fertilization (hpf) in ccm3 morphants (Fig. 2A). These vessels
were grossly enlarged in over 90% of embryos that were imaged
(n=62). Vessels remained abnormally large compared to wildtype
at later time points (72 hpf, data not shown). Central arteries also
appeared to be severely underdeveloped; however, pronounced dila-
tions were only seen in the PrA, MsV and AceV vessels. No gross mor-
phological defects other than the pericardial edema were observed in
morphant embryos, suggesting there was no non-speciﬁc toxicity
caused by the morpholino (Fig. 1A). The same ccm3a/b ATG MO
used in our work has been described as causing an early embryonic
lethality (Zheng et al., 2010), however we found that at the MO con-
centrations used in this study toxic effects were not found.Furthermore, an identical phenotype was observed when co-
injection of p53MOwas used to inhibit potential MO off-target effects
due to p53-mediated apoptosis (Robu et al., 2007). Cardiac pheno-
types (Fig. 1) were however noted at lower doses of ccm3a/b MO
(0.25 ng and above) than cranial vascular defects, which were mostly
apparent with 0.5–0.75 ng of ccm3a/b MO.
We imaged the cranial vasculature of the ccm3a/bmorphants at earlier
time points during development in order to investigate when the defects
ﬁrst arise. At 24 hpf, morphants display enlarged primordial midbrain
channels (PMCs), compared to wildtype (Fig. S1). At 36 hpf, an enlarged
midcerebral vein, which sprouts from the PMC, and later gives rise to
the MsVs, can be observed in ccm3a/b morphants (Fig. S1) (Ulrich et al.,
2011). To investigate whether these enlargements were due to an over-
proliferation of endothelial cells, we quantiﬁed the endothelial cell nuclei
in the affectedmesencephanlic veins in wildtype andmorphant embryos
at 54hpf, using the Tg(ﬂi1:nlsGFP) background (Fig. S3A). We found no
signiﬁcant change in endothelial cell numbers upon injection of the
ccm3a/bmorpholino (Fig. S3B, p-value=0.78), suggesting the phenotype
is likely due to defects in cell morphology.
Given the pericardial edema observed in ccm3a/b morphants, we
proceeded to analyze heart development in greater detail using a
cardiomyocyte-speciﬁc myl7:EGFP transgenic line. Contradictory to
previously published results, loss of ccm3a/b did not confer a dilated
heart phenotype characteristic of heart of glass (heg), ccm1 (san) or
ccm2 (vtn) mutants (Figs 1C, D). Morphant hearts were contractile
but failed to loop, and by 96–120 hpf had completely failed. Similar
results were achieved with co-injection of MOs targeting splicing of
ccm3a and b (data not shown). Using double transgenic kdrl:EGFP;
myl7:ras-cherry embryos, we also visualized the vessels connecting
the heart to the rest of the vasculature to further examine the reasons
behind the lack of circulation. ccm3a/b morphants in this transgenic
background displayed an apparent thinning and obstruction of the
ventral aorta and the ﬁrst aortic arches, suggesting that the circulato-
ry block is at the level of the ventral aorta (Fig. 1D).
To validate the speciﬁcity of our ccm3a/b ATGMO phenotypes, res-
cue experiments were next attempted. All ccm3a/b ATG MO pheno-
types, including pericardial edema, lack of circulation, and cranial
vasculature dilations could be rescued by co-injection of MO-
resistant mRNA encoding wildtype Ccm3b in the majority of injected
morphants (Figs. S2A and B). This indicated that ccm3a/b ATGMO de-
fects arose speciﬁcally due to loss of CCM3 function. Furthermore, in-
jection of N- or C-terminal truncated versions of ccm3mRNA failed to
rescue the MO phenotype, suggesting that the full-length CCM3 is
needed for its proper function (data not shown).
Given the cranial vasculature defects observed in ccm3a/b mor-
phants, we wished to more closely examine endothelial cells during
the onset of vessel dilation. We performed confocal imaging of the
ccm3a/b morphant cranial vasculature with a 40x objective. In 78%
of the imaged embryos (n=32) endothelial cells of the dilated
ccm3a/b morphant cranial vasculature projected a greater number
of membrane protrusions that were not evident in wildtype cells
(Fig. 2B, yellow arrows). While some minor enlargement of vessel di-
ameter was evident in 15–20% of san and vtn mutants, an elevated
protrusion phenotype was not observed. Further, cranial endothelial
cells in silent heart mutants appeared normal (Fig. 3J). The enhanced
protrusive phenotype observed in ccm3a/b morphants was therefore
speciﬁc to Ccm3, but not Ccm1 or 2, function, and was also not the re-
sult of reduced or absent blood ﬂow. The increase in the number and
length of endothelial membrane protrusions in ccm3a/b morphants
could also be clearly visualized in the kdrl:HsHRAS-mCherry; ﬂi1:
nlsEGFP double transgenic background using spinning disc confocal
microscopy with a 40x objective (Fig. 2C, yellow arrows). Quantiﬁca-
tion of these protrusions showed a signiﬁcant increase in their num-
ber per endothelial cell in morphant embryos compared to wildtype
(Fig. 2D, p=0.0046). At this magniﬁcation, wildtype embryos had a
properly lumenized cranial vasculature, whereas endothelial cells of
Fig. 1.Morpholino knockdown of ccm3a/b in zebraﬁsh embryos causes cardiovascular defects distinct from ccm1/2 mutants. (A) Light images of ccm3a/b morpholino injected em-
bryos at 54 hpf. Morphant embryos display a severe pericardial edema and complete circulatory block, but no gross morphological defects when injected with 0.25–0.75 ng ccm3a/b
ATGmorpholino. (B) Fluorescent microscopy images of ccm3a/bmorpholino injected and non-injected double transgenic kdrl:EGFP; gata1:dsRED embryos at 54 hpf. Morphants lack
circulation with blood pooling at the yolk. (C) Confocal images of the ccm3a/b morpholino injected Tg(myl7:EGFP)twu34 wildtype and ccm2 (valentine) mutant embryos. At 54 hpf,
ccm3a/b morphant hearts are dysmorphic but not enlarged, unlike the ccm2 (valentine) mutants whose hearts appear grossly dilated. (D) Confocal images of ccm3a/b morpholino
injected and non-injected double transgenic kdrl:EGFP, myl7:ras-cherry embryos. Injection of morpholino causes thinning of the ventral aorta and the ﬁrst aortic arches by 54 hpf.
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and in many cases not lumenized. In order to investigate the vessel
morphology in the ccm3a/b morphants further, we looked at the ex-
pression and distribution of zona occludens protein 1 (ZO-1), which
is essential for the assembly of tight junctions and a marker of endo-
thelial paracellular permeability. In wild-type MsVs, ZO-1 was found
to localize at tight junctions along the circumference of the vessel,
whereas in morphants, staining appeared more disorganized (Fig.
S3C). Furthermore, the failure of cranial vessel lumenization in mor-
phants could clearly be visualized in these optical sections.
The ccm3a/b cranial vasculature phenotype is not observed in ccm1,
ccm2 and silent heart mutants
In order to image the developing cranial vasculature in ccm1 and
ccm2 mutants, we next crossed transgenic kdrl:EGFP ﬁsh into san and
vtn backgrounds. Zebraﬁsh ccm1 (san) and ccm2 (vtn) mutants display
identical dilated heart phenotypes with equivalent defects in the vascu-
lature, including dilation of the sub-intestinal vessels and posterior car-
dinal vein (Hogan et al., 2008; Mably et al., 2006). Furthermore, as
perturbations in blood ﬂow have been shown to affect early zebraﬁshvascular development, we also examined silent heart (sih) mutant ﬁsh,
in which the heartbeat is absent (Sehnert et al., 2002). Neither san or
vtnmutant embryos displayed the severe cerebral vascular abnormali-
ties seen upon inhibition of ccm3a/b, suggesting that this phenotype is
speciﬁc to the loss of Ccm3 function (Fig. 3E–H) (for san, n=21, for
vtn, n=29). sih embryos similarly displayed no dilations in their cranial
vasculature (Fig. 3I, J) (n=25). This indicates the phenotype seen in
ccm3a/bmorphants is not simply due to a lack of blood ﬂow. Taken to-
gether, these data support a hypothesis that the ccm3 knockdown phe-
notype is distinct from that seen in ccm1 and ccm2mutants.
Knockdown of stk25b suggests a role in cardiovascular development
To examine if Ccm3 function in the cranial vasculature may be via
regulation of GCKIII family members, we next inhibited the two zeb-
raﬁsh stk25 orthologs (stk25a and stk25b) via MO injection. Despite
biochemical data that show a direct interaction between GCKIII pro-
teins and CCM3, the functional consequence of this interaction in
the cranial vasculature has not yet been explored in vivo. RNA in situ
hybridization analysis revealed that stk25b is maternally deposited
and broadly expressed until 24 hpf, when its transcripts become
Fig. 2.Morpholino knockdown of ccm3a/b causes gross dilation and mispatterning of cranial vessels. (A) At 54 hpf, confocal z-stack projections of dorsal head vasculature showed
enlargements in the prosencephalic arteries (PrA), mesencephalic veins (MsV), and anterior cerebral veins (AceV) in embryos injected with 0.75 ng ccm3a/b morpholino (>90%,
n=62). (B) Morpholino knockdown of ccm3a/b results in greater number of protrusions evident in endothelial cells of the dilated cranial vasculature (yellow arrows). (C) MsVs
of the wildtype and ccm3a/b morphant embryos imaged at higher magniﬁcation in kdrl:HsHRAS-mCherry; ﬂi1:nlsEGFP transgenic background. (D) ccm3a/b morphant embryos
have a signiﬁcantly higher number of cell protrusions per endothelial cell compared to wildtype (p-valueb0.01, n refers to number of embryos analyzed, with 3–5 cells counted
per embryo).
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stk25b in the brain and along the tail at 24 and 48 hpf is very similar to
the expression pattern for the ccm3a/b genes (Fig. S4), as well as
those published for the ccm1 and ccm2 genes (Mably et al., 2006;
Zheng et al., 2010).We performed morpholino-mediated knockdown of stk25a and
stk25b to further explore their role in the developing vasculature.
Loss of stk25a or b was found to result in defects in the cranial vascu-
lature (Fig. 4A). However enlargements in the PrAs, AceVs, and MsVs
were most apparent in stk25b morphants. stk25a morphants had
Fig. 3. The ccm3a/b cranial vasculature phenotype is speciﬁc to ccm3 function and not due to lack of blood ﬂow. Neither santa or valentine mutant embryos display severe vascular
dilations or mispatterning seen upon morpholino mediated ccm3a/b knockdown (for san, n=21, for vtn, n=32) (E-H) sih embryos similarly displayed no dilations in their cranial
vasculature (n=25) (I and J). Deep confocal z-stack projections (A, C, E, G and I) or z-stacks of dorsal views of the cranial vasculature (B, D, F, H and J) are shown.
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however, their vessels did not appear enlarged. stk25b morphants
had pericardial and venous plexus edemas similar to those seen
upon ccm3a/b knockdown, with no enlargement of the heart and a
largely normal blood circulation (Fig. 4B, and results not shown). On
the other hand, stk25amorphants had a very different gross morphol-
ogy, with apparent yolk extension and axis elongation defects
(Fig. 4B).
To examine the possible functional relationship between stk25b
and ccm3a/b, co-injection of low (non-phenotypic) levels of MOs
was used. Such analysis has previously been used to demonstrate
roles of pak2a and rap1 signaling in cranial vasculature integrity
(Gore et al., 2008). We injected amounts of ccm3a/b ATG (0.25 ng)
and stk25b (3 ng) MOs that resulted in singly injected embryos dis-
playing no appreciable cranial vasculature defects. In contrast, co-
injection of suboptimal ccm3a/b and stk25b MO levels resulted in a
large increase in the number of embryos that exhibit cranial dilations
(71%, n=83) (Fig. 5). This synergistic effect shows a cooperative ge-
netic interaction between ccm3a/b and stk25b, suggesting a mecha-
nistic link between Stk25b and Ccm3a/b in the cranial vasculature.
Co-injection of suboptimal stk25a and ccm3a/b MO levels severely
worsened the axis elongation defects; however, it did not lead to ap-
preciable cranial vessel dilations (data not shown).
Stk25bacts downstreamof Ccm3a/b for proper cardiovascular development
We next wished to test directly if Stk25 activity is downstream of
Ccm3a/b. Our low dose MO experiments, as well as the well-
established biochemical interaction between CCM3 and the members
of GCKIII family, suggest they may be downstream effectors of CCM3
signaling. To test this hypothesis, we performed rescue experiments
by overexpressing stk25bmRNA in ccm3a/bmorphant embryos. Strik-
ingly, co-injection of stk25b mRNA greatly ameliorated the ccm3a/b
ATG MO phenotype, with restoration of blood ﬂow to wildtype levels
and rescue of cranial vascular defects being evident (68% of embryos,
n=82) (Fig. 6). At higher ccm3a/bMO doses, cranial vasculature, but
not cardiac defects, were rescued by stk25b mRNA co-injection (data
not shown). This data suggests that Stk25b activity is downstream of
Ccm3 in the cranial vasculature.
Previous reports have suggested that CCM1, 2 and 3 function as
part of a shared protein complex to regulate vascular integrity
(Stahl et al., 2008; Voss et al., 2007). To determine whether Stk25b
is speciﬁcally required downstream of Ccm3, or whether it is a more
general component of a common CCM1/2/3 signaling pathway, wecarried out rescue experiments in ccm2 mutants. Overexpression of
stk25b mRNA, at levels sufﬁcient to fully rescue the ccm3a/b ATG
MO phenotype, failed to improve the ccm2 dilated heart phenotype,
and did not restore circulation (data not shown).
Combined loss of ccm2 and ccm3 activity results in exaggerated cranial
vasculature defects
The ability of Stk25b to rescue ccm3a/b, but not ccm2 loss-of-
function suggests that Ccm3 and Ccm2 may regulate vascular integri-
ty via distinct pathways. To formally test this model, suboptimal
(non-phenotypic) doses of ccm3a/b ATGMOwas injected into embry-
os obtained from a vtn heterozygous intercross in the kdrl:EGFP
background. Strikingly, we found that reduction of ccm3 function in
vtn/ccm2 null mutants, in every injected embryo, led to very severe
cranial vasculature defects, far more severe than those normally
observed following injection of higher doses of ccm3 MO (n=23)
(Fig. 7). This indicates that Ccm3 activity is still required in the ab-
sence of Ccm2 function, suggesting that Ccm2 and Ccm3 act via dis-
tinct pathways to regulate cranial vasculature morphogenesis in
zebraﬁsh.
Discussion
Increasing evidence suggests that CCM3 plays a different role than
CCM1 and CCM2 in vascular development. CCM1 and 2 have been
shown to exist in a complex and cause similar cardiovascular pheno-
types when they are absent in mouse and zebraﬁsh embryos
(Boulday et al., 2009; Mably et al., 2006; Stahl et al., 2008;
Whitehead et al., 2004, 2009; Zawistowski et al., 2005; Zhang et al.,
2007). In contrast, global deletion of mouse Ccm3 leads to embryonic
lethality at an earlier stage than seen in Ccm1 or Ccm2 null mice, due
to distinct vasculogenesis and hematopoiesis defects (Chan et al.,
2011; He et al., 2010). This agrees with human genotype-phenotype
analysis showing that CCM3 mutation carriers present a higher risk
for more severe hemorrhages, at an earlier (childhood) age of onset
(Denier et al., 2006). Furthermore, differences in cell biology and sig-
naling between CCM3 and CCM1/2 have been observed. Although loss
of CCM1 or 2 have been shown to result in increased RhoA signaling
and actin stress ﬁber formation, no indicators of RhoA activation
have been observed upon CCM3 depletion in human dermal micro-
vascular endothelial cells (HMVEC) (Chan et al., 2011). There is also
various biochemical data that supports the argument that the
CCM1/CCM2/CCM3 complex is not the only important signaling hub
Fig. 4. Morpholino knockdown of the GCKIII gene stk25b results in heart and vasculature defects similar to those seen in ccm3a/b morphants. (A) Confocal z-stack projections of
dorsal head vasculature of stk25a and stk25b morphants at 54 hpf. Injection of stk25a morpholino (2 ng) caused misconnections in cranial vasculature; however, no appreciable
vessel enlargements were observed. Injection of stk25bmorpholino (6 ng) caused dilation of prosencephalic arteries (PrA), anterior cerebral veins (AceV) and severe mispatterning
of the mesencephalic veins (MsV) in over 75% of the embryos imaged (yellow arrows, n>80). (B) Light images of stk25a and stk25bmorphants. stk25amorphants displayed a peri-
cardial edema, severe yolk extension and trunk elongation defects. The stk25b morphant phenotype was more similar to ccm3a/b morphant morphology, with pericardial and ve-
nous plexus edemas.
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2009; Kean et al., 2011; Rual et al., 2005; Voss et al., 2007). It is
known that CCM3 associates with the CCM1/CCM2 complex via inter-
action with CCM2. However, this interaction is in apparently substoi-
chiometric amounts, and represents only 1 possible CCM3 complex
that can form (Goudreault et al., 2009).
A number of biochemical functions have recently been ascribed to
CCM3. CCM3 has been shown to be a stoichiometric component of the
large STRIPAK complex, whose biological function is not yet clear
(Goudreault et al., 2009). Interestingly, CCM3 is the only CCM proteinfound in the STRIPAK complex, which suggests that besides potential-
ly participating in the common CCM1/CCM2 pathway, CCM3 likely
signals independently to perform additional roles. In one mouse
model, CCM3 has been shown to associate with, and regulate the ac-
tivity of, VEGFR2, whereas in a second independent mouse Ccm3mu-
tant this interaction was not observed (Chan et al., 2011; He et al.,
2010). In various models, CCM3 has been shown to have pro- and
anti-apoptotic activity (Chen et al., 2009; Fidalgo et al., 2010; Ma
et al., 2007). CCM3 has also been shown to regulate Golgi polarity in
cultured cells (Fidalgo et al., 2010). Relevant to this activity, CCM3 can
Fig. 5. Co-injection of suboptimal ccm3a/b (0.25 ng) and stk25b (3 ng) MO results in cranial vasculature defects at 54 hpf. Embryos injected with low doses of ccm3a/b (0.25 ng) or
stk25b morpholino (3 ng) showed no obvious defects in their cranial vessels (A-D). Co-injection of both morpholinos at the same dosages resulted in gross dilation of the prosen-
cephalic arteries (PrA), anterior cerebral veins (AceV), as well as enlargement and mispatterning of the mesencephalic veins (MsV) in 71% of the embryos (E–H, yellow arrows,
n=83).
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tivity (Fidalgo et al., 2010; Ma et al., 2007).
Given these pleiotropic activities for CCM3, an understanding of
how loss of ccm3 leads to CCMs clearly requires a disease-
appropriate model. In this report, we have shown that inhibition of
zebraﬁsh ccm3a/b leads to dilations of the embryonic cranial vascula-
ture, a phenotype strikingly reminiscent of the human disease. This
CCM3 function does not appear to be apoptosis-related, as inhibition
of p53 does not modify this phenotype. Further, the enlargements
seen in cranial vasculature in ccm3a/b morphants is not due to an
overproliferation of the endothelial cells, since the endothelial cell
nuclei number in morphant MsVs is comparable to wildtype (Figs.
S3A, B). The increased number of protrusions observed in ccm3a/b
morphant endothelial cells also does not appear to be related to a
lack of VEGFR2 signaling, but instead resembles what would be
expected with a hyperactivated receptor. Rescue of the ccm3a/b ATG
morpholino phenotype by injection of stk25b RNA, in contrast, points
to a clear mechanism for CCM3 function in endothelial cells. In the ab-
sence of any known STK25 substrates at present, there is no way toFig. 6. stk25b overexpression in ccm3a/b morphants rescues ccm3a/b cardiovascular
phenotype. Confocal z-stack projections of dorsal head vasculature in stk25b RNA
(200 pg) injected and non-injected ccm3a/bmorphants (0.5 ng ccm3a/b MO). Enlarge-
ment of the PrA and AceV in the vasculature were decreased in 68% of ccm3a/b mor-
phants upon injection of stk25b mRNA (A–D, yellow arrows, n=82).conclusively show if CCM3 activates or inhibits STK25 function. How-
ever, our data clearly suggest a stimulatory and direct effect of CCM3
on STK25 activity. The ability of exogenous Stk25b to rescue the ab-
sence of Ccm3 function may either reﬂect a sufﬁcient localized con-
centration of Stk25b being achieved (if Ccm3 is required for Stk25
localization or stability) or activity threshold being met (if Ccm3 acti-
vates Stk25 directly) for proper zebraﬁsh vascular development to
proceed. CCM3 has been shown to associate with a number of com-
plexes/proteins (STRIPAK, CCM2 and Paxillin) via its C-terminal FAT
domain (Goudreault et al., 2009; Li et al., 2010; Voss et al., 2007).
While not formally tested, these interactions may be mutually exclu-
sive, such that the activity of CCM3 (and its associated kinase) in a
given cell may be highly context-dependent. In this context, it is in-
teresting to note that in stk25b morphant embryos the ccm3 cranial
vasculature, but not cardiac/circulatory, defects were observed.
CCM3 function may be highly context-dependent, highlighting the
need to study CCM disease pathogenesis in the correct models. Future
work aimed at elucidating STK25 phosphorylation targets and the lo-
calization of CCM3 and STK25 in endothelial cells will be key in gain-
ing a further understanding of CCM3 function in CCM disease.
It should of course be noted that our results contrast with previous
reports of ccm3MO knockdown in zebraﬁsh, which showed a ccm1/2-
like large heart phenotype (Voss et al., 2009; Zheng et al., 2010). We
have assayed several MOs targeting ccm3a and b, with all yielding
similar and reproducible phenotypes, both between MOs and investi-
gator. Further, we can rescue our MO phenotypes via injection of both
MO-resistant ccm3 RNA and stk25b RNA. Given that we have carefully
controlled for our MO experiments, and in addition carefully titrated
MO levels to alleviate toxic off-target effects, we are conﬁdent in the
morpholino phenotypes we have presented. One possible explanation
for these discrepancies is that a splice site MOwas used extensively in
previous studies, which resulted in a truncated Ccm3 being formed. It
may be that this Ccm3 species has dominant negative activity. Given
the more recent demonstration of different in vivo phenotypes for
Ccm3 and Ccm1/2 loss in the mouse, and potential in vitro differences
in CCM3 and CCM1/2 activity, we feel that our work, in a disease-like
model, highlights what will be an important avenue of research in fu-
ture for the CCM (and vascular development) ﬁeld.
In this paper, we report that morpholino-mediated knockdown of
ccm3a/b causes severe dilations in zebraﬁsh cranial vasculature. This
phenotype is distinct from those of the published zebraﬁsh ccm1
and ccm2 mutants, and recapitulates key aspects of the human CCM
disease. Our results show that, contrary to previous reports, ccm3
Fig. 7. Injection of suboptimal doses of ccm3a/b ATG morpholino into ccm2/vtn mutants results in very severe cranial vascular defects. Gross dilations of the AceV, PrA and MsV
vessels were observed upon injection of 0.25 ng ccm3a/b ATG morpholino into ccm2/vtn embryos (A–H, yellow arrows).
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ccm1/2 mutants. Notably, we have found that ccm3 morphant cranial
endothelial cells often have defects in lumen formation, an activity
not reported for CCM1/2 in cultured endothelial cell models. Our
ZO-1 staining in ccm3a/b morphants further suggest that establish-
ment of endothelial cell-cell junctions could be defective in these
morphants. We also show that knockdown of ccm3 causes endothelial
cells of the cranial vasculature to form an elevated number of protru-
sions, which is not seen in ccm1/2mutants. During the migration and
assembly of endothelial cells into vessels, these cells extend actin-rich
membrane protrusions such as ﬁlopodia and lamellipodia. However,
once the proper connections are made between the cells, there
needs to be a downregulation of this protrusive activity to establish
and maintain the integrity of the newly formed vessels (Holderﬁeld
and Hughes, 2008; Lamalice et al., 2007). Knockdown of ccm3 also ap-
pears to affect the organization of endothelial cells into a lumenized
network. The increased membrane protrusions seen in ccm3a/b mor-
phants could indicate a failure in regulating actin cytoskeletal dynam-
ics. Furthermore, along with the lack of proper vessel lumenization
and aberrant ZO-1 staining, it could be due to defects in the general
polarity of endothelial cells. Interestingly, a recent report investigat-
ing the function of CCM2 and CCM3 in regulating angiogenesis dem-
onstrated dramatic growth and extension of endothelial cell sprouts
upon siRNA silencing of CCM3 in both HUVEC and CCM-patient de-
rived cells (Zhu et al., 2010). A recent analysis of endothelial cells de-
pleted of CCM1, 2 or 3 also showed that loss of CCM3 in particular,
yields cells with a rounded, multi-protrusive appearance (Borikova
et al., 2010). The mechanism behind this sprout growth is not yet
clear; however, our data indicates that this phenotype is also ob-
served in vivo. Further work is needed to determine the molecular ef-
fectors downstream of Stk25 and the speciﬁc cellular defects caused
by disruption of Ccm3/Stk25 signaling.
Perhaps our most compelling data for distinct CCM3 and CCM1/2
functions in the cranial vasculature is the striking enhancement of cra-
nial vasculature dilations observed when sub-phenotypic amounts of
ccm3a/b ATG morpholino was injected into ccm2 (valentine) mutants.
This represents, to our knowledge, the ﬁrst reported analysis of com-
bined loss of Ccm3 and Ccm1/2. This data, combinedwith stk25b rescue
of ccm3a/bmorphants (but not ccm2mutants) suggests a model where
CCM1/2 and CCM3/STK25 signaling make up two distinct arms of the
CCM pathway that helps regulate the development and stabilization
of the cranial vasculature.Workwith cultured endothelial cells has sug-
gested thatwhile CCM1, 2 and 3may all affect RhoA protein levels, they
may regulate Rho activity (and other signaling events) in distinct ways(Borikova et al., 2010). Furthermore, more recent work showed a strik-
ing defect in lumen formation upon knockdown of CCM3 or GCKIII ki-
nases, suggesting that CCM3 signaling is distinct from the CCM2-RhoA
pathway (Chan et al., 2011). A distinct possibility is that the disease
endpoint (CCMs) may be reached via entirely distinct means following
loss of CCM1/2 or CCM3. As a recent report suggests a non-autonomous
(i.e. not in endothelial cells) function for CCM3 in disease pathogenesis
(Louvi et al., 2011), this concept should clearly be examined in greater
detail. An important implication of this for CCM disease is that not all
patients may respond to a given therapeutic agent to the same extent.
For example, given the recent promise of Rho pathway inhibition by
agents such as Fasudil and Statins (Stockton et al., 2010; Whitehead
et al., 2009), it may be that CCM3 pathway-mediated CCMs will not
be as responsive to these therapies. Perhaps, for example, Ccm1/2
act on cell adhesion via a Rho-mediated pathway, whereas Ccm3 affects
endothelial cell lumenization in a Stk25-dependent manner. Given
the strong effect we observed when inhibiting both the Ccm1/2 and
Ccm3 pathways simultaneously, a further delineation of the CCM3 sig-
naling pathway will in the future present new possible genetic modi-
ﬁers and disease genes for familial and sporadic CCM disease.
Impairment of both pathways may therefore lead to more severe dis-
ease progression.
Our zebraﬁsh ccm3 model presents, we believe, an excellent tool
to study the development of CCMs in real time. The vascular lesions
we have observed develop quickly (over the course of 72 hours) in
a transparent embryo, where the vasculature can be readily imaged.
The study of CCMs has largely been limited to end point clinical sam-
ples and cultured endothelial cells. As such, the key events that lead
to the disease phenotype are not clear at present. Future research
on zebraﬁsh ccm3morphants will allow the imaging and mechanistic
study of how endothelial dysfunction ﬁrst arises, and how the disease
is precipitated. It is not clear why CCM-like vascular dilations are not
present in ccm1 or 2 mutant zebraﬁsh embryos. It may be that, much
like in the human disease, the onset of vascular dysfunction in zebra-
ﬁsh occurs more quickly with reduction of Ccm3 function. Given the
embryonic lethality of ccm1 and 2 mutants (due to cardiac defects),
cranial vasculature defects, which may have arisen later in develop-
ment or adult life, would therefore not be evident. It will be of interest
in the future to examine the cranial vasculature of heterozygous mu-
tant ccm1, 2 and (when available) 3 adult zebraﬁsh. Finally, the zebra-
ﬁsh embryo is highly amenable to large-scale chemical genetic
screens. Zebraﬁsh CCM models may therefore be of great use to ﬁnd
potential therapeutic agents that target either the initiation or pro-
gression of disease.
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